Cargando…

Current use of statins reduces risk of HIV rebound on suppressive HAART

BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-V...

Descripción completa

Detalles Bibliográficos
Autores principales: Drechsler, Henning, Ayers, Colby, Cutrell, James, Maalouf, Naim, Tebas, Pablo, Bedimo, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331966/
https://www.ncbi.nlm.nih.gov/pubmed/28249009
http://dx.doi.org/10.1371/journal.pone.0172175
_version_ 1782511461948456960
author Drechsler, Henning
Ayers, Colby
Cutrell, James
Maalouf, Naim
Tebas, Pablo
Bedimo, Roger
author_facet Drechsler, Henning
Ayers, Colby
Cutrell, James
Maalouf, Naim
Tebas, Pablo
Bedimo, Roger
author_sort Drechsler, Henning
collection PubMed
description BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-Veterans who started HAART 1995–2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months. We defined virologic failure (VF) as the first VL >1,000 copies/mL or the first of 2 consecutive VL >200 copies/mL. We built a time-updated drug exposure model for antiretrovirals (ARVs), statins, and other cardiovascular drugs (CVMs), investigating current use (yes/no), recent use (proportion of days used), and categorical use (ever/never). We used both multiply adjusted and inverse-probability-weighted (IPW) Cox models to explore the association between statin and CVM use and VF. RESULTS: 19,324 veterans met inclusion criteria. Median follow-up was 13 months (IQR: 5–32 months); 63% experienced VF after a median time of 9 months (IQR 4–21 months). Almost 1/3 patients ever used statins but exposure comprised only 41% of follow-up time covered after initial prescription. Unadjusted, current statin use was associated with a hazard ratio (HR) for VF of 0.60 (CI: 0.56–0.65). This remained statistically significant after multivariate adjustment (MVA) for demographics, HIV and HAART parameters [HR 0.81 (CI: 0.75–0.88), p<0.001] and IPW (truncation <1%/>99%) HR: 0.83 (CI: 0.75–0.92), p<0.001]. No independent association was observed for other CVMs. The association between categorical-statin use and VF after MVA was much weaker: HR 0.94 (CI: 0.88–1.00, p = 0.04). CONCLUSION: Current statin exposure was associated with reduced risk of VF in univariate, multivariate, and inverse-probability-weighted models. Our results highlight the importance of time-updated medication exposure models for observational studies.
format Online
Article
Text
id pubmed-5331966
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53319662017-03-10 Current use of statins reduces risk of HIV rebound on suppressive HAART Drechsler, Henning Ayers, Colby Cutrell, James Maalouf, Naim Tebas, Pablo Bedimo, Roger PLoS One Research Article BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-Veterans who started HAART 1995–2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months. We defined virologic failure (VF) as the first VL >1,000 copies/mL or the first of 2 consecutive VL >200 copies/mL. We built a time-updated drug exposure model for antiretrovirals (ARVs), statins, and other cardiovascular drugs (CVMs), investigating current use (yes/no), recent use (proportion of days used), and categorical use (ever/never). We used both multiply adjusted and inverse-probability-weighted (IPW) Cox models to explore the association between statin and CVM use and VF. RESULTS: 19,324 veterans met inclusion criteria. Median follow-up was 13 months (IQR: 5–32 months); 63% experienced VF after a median time of 9 months (IQR 4–21 months). Almost 1/3 patients ever used statins but exposure comprised only 41% of follow-up time covered after initial prescription. Unadjusted, current statin use was associated with a hazard ratio (HR) for VF of 0.60 (CI: 0.56–0.65). This remained statistically significant after multivariate adjustment (MVA) for demographics, HIV and HAART parameters [HR 0.81 (CI: 0.75–0.88), p<0.001] and IPW (truncation <1%/>99%) HR: 0.83 (CI: 0.75–0.92), p<0.001]. No independent association was observed for other CVMs. The association between categorical-statin use and VF after MVA was much weaker: HR 0.94 (CI: 0.88–1.00, p = 0.04). CONCLUSION: Current statin exposure was associated with reduced risk of VF in univariate, multivariate, and inverse-probability-weighted models. Our results highlight the importance of time-updated medication exposure models for observational studies. Public Library of Science 2017-03-01 /pmc/articles/PMC5331966/ /pubmed/28249009 http://dx.doi.org/10.1371/journal.pone.0172175 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Drechsler, Henning
Ayers, Colby
Cutrell, James
Maalouf, Naim
Tebas, Pablo
Bedimo, Roger
Current use of statins reduces risk of HIV rebound on suppressive HAART
title Current use of statins reduces risk of HIV rebound on suppressive HAART
title_full Current use of statins reduces risk of HIV rebound on suppressive HAART
title_fullStr Current use of statins reduces risk of HIV rebound on suppressive HAART
title_full_unstemmed Current use of statins reduces risk of HIV rebound on suppressive HAART
title_short Current use of statins reduces risk of HIV rebound on suppressive HAART
title_sort current use of statins reduces risk of hiv rebound on suppressive haart
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331966/
https://www.ncbi.nlm.nih.gov/pubmed/28249009
http://dx.doi.org/10.1371/journal.pone.0172175
work_keys_str_mv AT drechslerhenning currentuseofstatinsreducesriskofhivreboundonsuppressivehaart
AT ayerscolby currentuseofstatinsreducesriskofhivreboundonsuppressivehaart
AT cutrelljames currentuseofstatinsreducesriskofhivreboundonsuppressivehaart
AT maaloufnaim currentuseofstatinsreducesriskofhivreboundonsuppressivehaart
AT tebaspablo currentuseofstatinsreducesriskofhivreboundonsuppressivehaart
AT bedimoroger currentuseofstatinsreducesriskofhivreboundonsuppressivehaart